AR091027A1 - Analogos de benzomorfano y el usos de estos - Google Patents
Analogos de benzomorfano y el usos de estosInfo
- Publication number
- AR091027A1 AR091027A1 ARP130101641A ARP130101641A AR091027A1 AR 091027 A1 AR091027 A1 AR 091027A1 AR P130101641 A ARP130101641 A AR P130101641A AR P130101641 A ARP130101641 A AR P130101641A AR 091027 A1 AR091027 A1 AR 091027A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- elements
- halo
- coor7
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Compuestos análogos de benzomorfano de la fórmula --------- en donde R1, R2a, R2b, R3, R4, Z y G son como se definen en la presente. Los compuestos son útiles para tratar dolor, constipación y otras condiciones moduladas por la actividad de los receptores opioides y ORL-1. Reivindicación 1: Un compuesto de la fórmula (1), en donde R¹ se elige del grupo que consiste en -alquilo C₁₋₁₀, -alquenilo C₂₋₁₀, -alquinilo C₂₋₁₀, -cicloalquilo C₃₋₁₂, cicloalquil C₃₋₁₂-alquilo C₁₋₆, -cicloalquenilo C₃₋₁₂, cicloalquenil C₃₋₁₂-alquilo C₁₋₆, -arilo (de 6 a 14 elementos), (arilo (de 6 a 14 elementos))-alquilo C₁₋₆, -(OCH₂CH₂)ₛ-O-alquilo C₁₋₆, -(CH₂CH₂O)ₛ-alquilo C₁₋₆, alcoxi C₁₋₁₀, C₍ₕₐₗₒ₎₃, CH(halo)₂, CH₂(halo), C(O)R⁵, C(O)O-alquilo C₁₋₁₀, y -(CH₂)ₙ-N(R⁶)₂, en donde cada uno es sustituido opcionalmente por 1, 2 ó 3 R⁹ grupos seleccionados de manera independiente; R²ᵃ y R²ᵇ son, cada uno, seleccionados de manera independiente de: (a) -H; o (b) -alquilo C₁₋₅, -alquenilo C₂₋₅, o -alquinilo C₂₋₅; Z está ausente o -(CH₂)ₘ-, opcionalmente sustituido por 1 ó 2 -alquilo C₁₋₆ elegidos en forma independiente; G se elige del grupo que consiste en: e) un enlace, -alquileno C₁₋₆, -alquenileno C₂₋₆; o f) O, -OCO-, -C(=O); o g) NR⁸; o h) S, SO y SO₂; R³ se elige del grupo que consiste en hidrógeno, -alquilo C₁₋₁₀, -alquenilo C₂₋₁₂, -C(=O), C(=O)-alquilo C₁₋₆, -C(=O)-alquilo C₁₋₆, -C(=O)-arilo (de 6 a 14 elementos), -C(=O)-heteroarilo (de 5 a 12 elementos), -alquinilo C₂₋₁₂, -alcoxi C₁₋₁₀, -(OCH₂CH₂)ₛ-O-alquilo C₁₋₆, -(CH₂CH₂O)ₛ-alquilo C₁₋₆, -NH₂, -NH-alquilo C₁₋₆, CN, -CONR⁵R⁶, -alquilo C₁₋₆CONR⁵R⁶, -COOR⁷, -alquil C₁₋₆-COOR⁷, -alcoxi C₁₋₆-COOR⁷, -C(=O)-(CH₂)ₙ-COOR⁷, -C(=O)-(CH₂)ₙ-CONR⁵R⁶, -cicloalquilo C₃₋₁₂, (cicloalquilo C₃₋₁₂)-alquilo C₁₋₆, -cicloalquenilo C₄₋₁₂, (cicloalquenilo C₄₋₁₂)-alquilo C₁₋₆, -bicicloalquilo C₆₋₁₄, (bicicloalquilo C₆₋₁₄)-alquilo C₁₋₆, -tricicloalquilo C₅₋₂₀, (tricicloalquilo C₈₋₂₀)-alquilo C₁₋₆, -bicicloalquenilo C₇₋₁₄, (bicicloalquenilo C₇₋₁₄)-alquilo C₁₋₆, -tricicloalquenilo C₈₋₂₀, (tricicloalquenilo C₈₋₂₀)-alquilo C₁₋₆, -arilo (de 6 a 14 elementos), (arilo (de 6 a 14 elementos))-alquilo C₁₋₆, -sistema de anillo bicíclico (de 7 a 12 elementos), (sistema de anillo bicíclico (de 7 a 12 elementos))-alquilo C₁₋₆, -arilo bicíclico (de 7 a 12 elementos), (arilo bicíclico (de 7 a 12 elementos))-alquilo C₁₋₆, -heteroarilo (de 5 a 12 elementos), (heteroarilo (de 5 a 12 elementos))-alquilo C₁₋₆, -heterociclo (de 3 a 12 elementos), (heterociclo (de 3 a 12 elementos))-alquilo C₁₋₆, -bicicloheterociclo (de 7 a 12 elementos), (bicicloheterociclo (de 7 a 12 elementos))-alquilo C₁₋₆, fenilo, bencilo y naftilo; en donde cada uno es opcionalmente sustituido por uno, dos o tres sustituyentes seleccionados de manera independiente del grupo que consiste en -OH, (=O), halo, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -alquilo C₁₋₆, haloalquilo C₁₋₆, -alquenilo C₂₋₆, -alquinilo C₂₋₆, hidroxialquilo C₁₋₆, dihidroxialquilo C₁₋₆, -alcoxi C₁₋₆, (alcoxi C₁₋₆)-C(=O)-alcoxi C₁₋₆-, fenilo, bencilo, -NH₂, -NR⁵R⁶, -NH-alquilo C₁₋₆, -alquil C₁₋₆-NH-alquil C₁₋₆-R¹⁴, -CN, -SH, -OR⁴, -CONR⁵R⁶, -(alquilo C₁₋₆)-C(=O)-NR⁵R⁶, -COOR⁷, -alquil C₁₋₆-COOR⁷, -alcoxi C₁₋₆-COOR⁷, -(OCH₂CH₂)ₛ-O-alquilo C₁₋₆, -(CH₂CH₂O)ₛ-alquilo C₁₋₆, (alquilo C₁₋₆)sulfonil-alquilo C₁₋₆, -NH-SO₂-alquilo C₁₋₆, -N-(SO₂-alquilo C₁₋₆)₂, -C(=NH)-NH₂, -NH-C(=O)-alquilo C₁₋₆, -NH-C(=O)-NH₂, -NH-C(=O)-NH-alquilo C₁₋₆, -NH-C(=O)-arilo (de 6 a 14 elementos), -NH-C(=O)-alquil C₁₋₆-arilo (de 6 a 14 elementos), -NH-alquil C₁₋₆-COOR⁷, -NH-C(=O)-alquil C₁₋₆-COOR⁷, -NH-C(=O)-CH(NH₂)-alquil C₁₋₆-C(=O)-OR⁷, -cicloalquilo C₃₋₁₂, (cicloalquilo C₃₋₁₂)-alquilo C₁₋₆, -arilo (de 6 a 14 elementos), -ariloxi (de 6 a 14 elementos), -alcoxi C₁₋₆C₍₌O₎NR⁵R⁶, -NH-alquilo C₁₋₆-C(O)-NR⁵R⁶, -C(O)NH-alquil C₁₋₆-COOR⁷, (arilo (de 6 a 14 elementos))-alquilo C₁₋₆, -heteroarilo (de 5 a 12 elementos), (heteroarilo (de 5 a 12 elementos))-alquilo C₁₋₆, -heterociclo (de 3 a 12 elementos), (heterociclo (de 3 a 12 elementos))-alquilo C₁₋₆, -bicicloheterociclo (de 7 a 12 elementos), y (bicicloheterociclo (de 7 a 12 elementos))-alquilo C₁₋₆; R⁴ se elige de (c) -H, -OH, halo, -C(halo)₃, -CH(halo)₂, -CH₂(halo), COOH, o CONH₂; o (d) -alquilo C₁₋₅, -alquenilo C₂₋₅, -alquinilo C₂₋₅, -(CH₂)ₙ-O-(CH₂)ₙ-CH₃, o -alcoxi C₁₋₅, en donde cada uno es opcionalmente sustituido por 1, 2 ó 3 grupos R⁹ seleccionados de manera independiente; R⁵ y R⁶ son, cada uno, seleccionados de manera independiente de (e) hidrógeno, -OH, halo, -C(halo)₃, -CH(halo)₂, -CH₂(halo); o (f) -alquilo C₁₋₆, -alquenilo C₂₋₅, -alquinilo C₂₋₅, -(CH₂)ₙ-O-(CH₂)ₙ-CH₃, -alcoxi C₁₋₆, en donde cada uno es opcionalmente sustituido por 1, 2 ó 3 grupos R⁹ seleccionados de manera independiente; o (g) -cicloalquilo C₃₋₈, (cicloalquilo C₃₋₈)-alquilo C₁₋₆, -COOR⁷, -alquil C₁₋₆-COOR⁷, -CONH₂, o alquil C₁₋₆-CONH-; o (h) R⁵ y R⁶ junto con el átomo de nitrógeno al que están unidos forman un heterociclo (de 4 a 8 elementos); R⁷ se elige del grupo que consiste en hidrógeno, -alquilo C₁₋₆, -alquenilo C₂₋₆, -alquinilo C₂₋₆, -cicloalquilo C₃₋₁₂, -cicloalquenilo C₄₋₁₂, (cicloalquilo C₃₋₁₂)-alquilo C₁₋₆, y (cicloalquenilo C₄₋₁₂)-alquilo C₁₋₆; R⁸ se elige de H, -alquilo C₁₋₆, -alquenilo C₂₋₆, -alquinilo C₂₋₆, -alcoxi C₁₋₁₀, -cicloalquilo C₃₋₁₂, -cicloalquenilo C₃₋₁₂, (cicloalquilo C₃₋₁₂)-alquilo C₁₋₆, (cicloalquenilo C₃₋₁₂)-alquilo C₁₋₆, -C(=O)alquilo C₁₋₆ o SO₂-alquilo C₁₋₆; cada R⁹ es seleccionado de manera independiente de -OH, halo, -alquilo C₁₋₁₀, -alquenilo C₂₋₁₀, -alquinilo C₂₋₁₀, -alcoxi C₁₋₁₀, -cicloalquilo C₃₋₁₂, -CHO, -C(O)OH, -C(halo)₃, -CH(halo)₂, CH₂(halo), o -(CH₂)ₙ-O-(CH₂)ₙ-CH₃; cada R¹⁴ se elige en forma independiente del grupo que consiste en -COOR⁷, -alquil C₁₋₆-COOR⁷, -C(=O)-alquil C₁₋₆-COOR⁷, -alquil C₁₋₆-C(=O)-alquil C₁₋₆-COOR⁷, CONH₂, y -alquil C₁₋₆-CONH; m es un entero 1, 2, 3, 4, 5 ó 6; n es un entero 0, 1, 2, 3, 4, 5 ó 6; s es un entero 1, 2, 3, 4, 5 ó 6; y las sales y so
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261646068P | 2012-05-11 | 2012-05-11 | |
US201361778091P | 2013-03-12 | 2013-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091027A1 true AR091027A1 (es) | 2014-12-30 |
Family
ID=48577149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101641A AR091027A1 (es) | 2012-05-11 | 2013-05-10 | Analogos de benzomorfano y el usos de estos |
Country Status (7)
Country | Link |
---|---|
US (2) | US20150210646A1 (es) |
EP (1) | EP2858976B1 (es) |
JP (1) | JP6114382B2 (es) |
AR (1) | AR091027A1 (es) |
CA (1) | CA2870605A1 (es) |
TW (1) | TW201408645A (es) |
WO (1) | WO2013167963A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2619212T3 (en) | 2010-09-21 | 2016-03-21 | Purdue Pharma Lp | BUPRENORPHINANALOGER AS opioid receptor agonists and / or antagonists |
JP6400592B2 (ja) | 2012-11-09 | 2018-10-03 | パーデュー、ファーマ、リミテッド、パートナーシップ | ベンゾモルファン類似体およびその使用 |
TW201434842A (zh) | 2012-12-07 | 2014-09-16 | Purdue Pharma Lp | 丁基原啡因(buprenorphine)類似物類 |
JP6141444B2 (ja) | 2012-12-14 | 2017-06-07 | パーデュー、ファーマ、リミテッド、パートナーシップ | スピロ環式モルフィナンおよびこれらの使用 |
EP2931724B1 (en) | 2012-12-14 | 2017-01-25 | Purdue Pharma LP | Pyridonemorphinan analogs and biological activity on opioid receptors |
JP6182620B2 (ja) * | 2013-01-31 | 2017-08-16 | パーデュー、ファーマ、リミテッド、パートナーシップ | ベンゾモルファン類似体およびその使用 |
US8969358B2 (en) | 2013-03-15 | 2015-03-03 | Purdue Pharma L.P. | Buprenorphine analogs |
WO2015079459A1 (en) * | 2013-11-27 | 2015-06-04 | Nektar Therapeutics (India) Pvt.Ltd. | Opioid agonists and uses thereof |
WO2015097545A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans |
EP3087073B1 (en) | 2013-12-26 | 2018-07-04 | Purdue Pharma LP | 10-substituted morphinan hydantoins |
EP3087078B1 (en) | 2013-12-26 | 2019-05-15 | Purdue Pharma LP | 7-beta-alkyl analogs of orvinols |
US9656962B2 (en) | 2013-12-26 | 2017-05-23 | Purdue Pharma L.P. | Ring-contracted morphinans and the use thereof |
WO2015099863A1 (en) | 2013-12-27 | 2015-07-02 | Purdue Pharma L.P. | 6-substituted and 7-substituted morphinan analogs and the use thereof |
US9975854B2 (en) * | 2014-05-06 | 2018-05-22 | Purdue Pharma L.P. | Benzomorphan analogs and use thereof |
US10030021B2 (en) | 2014-05-27 | 2018-07-24 | Purdue Pharma L.P. | Spirocyclic morphinans and use thereof |
JP6360915B2 (ja) | 2014-06-13 | 2018-07-18 | パーデュー、ファーマ、リミテッド、パートナーシップ | アザモルフィナン誘導体及びその使用 |
WO2016044546A1 (en) * | 2014-09-17 | 2016-03-24 | Purdue Pharma L.P. | Benzomorphan analogs and the use thereof |
MA41125A (fr) | 2014-12-05 | 2017-10-10 | Purdue Pharma Lp | Dérivés de 6.7-cyclomorphinane et leur utilisation |
WO2018125716A1 (en) | 2017-01-02 | 2018-07-05 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
EP4001280A4 (en) | 2019-07-19 | 2023-07-12 | Nippon Chemiphar Co., Ltd. | PROCESS FOR THE PRODUCTION OF PHENOL DERIVATIVES |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3480638A (en) * | 1966-11-10 | 1969-11-25 | Geigy Chem Corp | Derivatives of 5-hydroxyalkyl-6,7-benzomorphans |
US3480338A (en) * | 1967-11-13 | 1969-11-25 | Caterpillar Tractor Co | Seals for track link assemblies |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3883536A (en) * | 1970-05-27 | 1975-05-13 | Acf Chemiefarma Nv | 3,3-Disubstituted-2-benzyl-4-piperidinols |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3891657A (en) * | 1972-10-26 | 1975-06-24 | Bristol Myers Co | 9Beta-hydroxy-5-methyl-6,7-benzomorphans |
US3853887A (en) * | 1973-03-09 | 1974-12-10 | Universal Oil Prod Co | Cyclialkylation of amines |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3932422A (en) * | 1974-05-20 | 1976-01-13 | Sterling Drug Inc. | 8-Methylene-3-azabicyclo[3.3.1]non-6-en-4-ones |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
NL7907800A (nl) | 1979-10-23 | 1981-04-27 | Acf Chemiefarma Nv | Nieuwe 6,7-benzomorfanderivaten en zuuradditiezouten daarvan, farmaceutische preparaten die een dergelijke verbinding bevatten, alsmede werkwijze voor het bereiden van deze verbindingen en de farmaceutische preparaten. |
DE2943805A1 (de) | 1979-10-30 | 1981-05-27 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von 3-phenoxy-benzaldehyden |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
DE69635048T2 (de) | 1995-06-12 | 2006-02-16 | G.D. Searle & Co. | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
DE69826278T2 (de) | 1997-05-30 | 2005-11-10 | Banyu Pharmaceutical Co., Ltd. | 2-oxoimidazol-derivate |
US6410561B1 (en) | 1998-03-26 | 2002-06-25 | Japan Tobacco Inc. | Amide derivatives and nociceptin antagonists |
DE19826365A1 (de) * | 1998-06-12 | 1999-12-16 | Gruenenthal Gmbh | Verwendung von Benzomorphanderivaten als Analgetikum |
EP2225246A1 (en) * | 2007-11-30 | 2010-09-08 | Purdue Pharma LP | Benzomorphan compounds |
EP2245014B1 (en) * | 2008-02-12 | 2011-11-02 | Boehringer Ingelheim International GmbH | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
US9975854B2 (en) * | 2014-05-06 | 2018-05-22 | Purdue Pharma L.P. | Benzomorphan analogs and use thereof |
-
2013
- 2013-05-10 US US14/400,129 patent/US20150210646A1/en not_active Abandoned
- 2013-05-10 JP JP2015510887A patent/JP6114382B2/ja not_active Expired - Fee Related
- 2013-05-10 AR ARP130101641A patent/AR091027A1/es unknown
- 2013-05-10 WO PCT/IB2013/000948 patent/WO2013167963A1/en active Application Filing
- 2013-05-10 EP EP13727342.1A patent/EP2858976B1/en active Active
- 2013-05-10 TW TW102116698A patent/TW201408645A/zh unknown
- 2013-05-10 CA CA2870605A patent/CA2870605A1/en not_active Abandoned
-
2017
- 2017-09-13 US US15/703,453 patent/US20180127374A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2870605A1 (en) | 2013-11-14 |
US20180127374A1 (en) | 2018-05-10 |
US20150210646A1 (en) | 2015-07-30 |
EP2858976B1 (en) | 2018-03-14 |
TW201408645A (zh) | 2014-03-01 |
JP6114382B2 (ja) | 2017-04-12 |
JP2015516410A (ja) | 2015-06-11 |
EP2858976A1 (en) | 2015-04-15 |
WO2013167963A1 (en) | 2013-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR091027A1 (es) | Analogos de benzomorfano y el usos de estos | |
AR094641A1 (es) | Análogos de buprenorfina | |
AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
AR072249A1 (es) | Inhibidores de amida hidrolasa de acido graso. usos. metodos. | |
AR090548A1 (es) | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k | |
AR100244A1 (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
AR088023A1 (es) | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO | |
AR062011A1 (es) | Derivados de diazol y sus composiciones como inhibidores de itpkb | |
AR094646A1 (es) | Morfinanos sustituidos y su uso | |
AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
AR112834A1 (es) | Derivados de rapamicina | |
AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
AR092607A1 (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
AR078153A1 (es) | Compuestos y composiciones como moduladores de la actividad de tlr | |
AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
AR094929A1 (es) | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 | |
AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
AR091022A1 (es) | Inhibidores del nampt | |
AR086792A1 (es) | Compuestos para el tratamiento de la adiccion | |
AR093832A1 (es) | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO | |
AR093504A1 (es) | 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos | |
AR108387A1 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |